Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpressing FGFR2b

2024-516724-33-00 Protocol ANGELICA / ET24-224 Phase I and Phase II (Integrated) - Other Ended

End 7 Nov 2025 · Status Ended · 1 EU/EEA countries · 17 sites · Protocol ANGELICA / ET24-224

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 87
Countries 1
Sites 17

Advanced/metastatic gynecological cancer overexpressing FGFR2b

Key facts

Sponsor
Centre Leon Berard
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
completed 7 Nov 2025
Decision date (initial)
2025-07-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced/metastatic gynecological cancer overexpressing FGFR2b

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Leon Berard

Sponsor organisation
Centre Leon Berard
Address
28 Rue Laennec
City
Lyon
Postcode
69008
Country
France

Scientific contact point

Organisation
Centre Leon Berard
Contact name
Pr Ray-Coquard

Public contact point

Organisation
Centre Leon Berard
Contact name
Project manager

Locations

1 EU/EEA country · 17 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 87 17
Rest of world 0

Investigational sites

France

17 sites · Ended
Institut Regional Du Cancer De Montpellier
Medical oncology, 208 Avenue Des Apothicaires, 34298, Montpellier Cedex 5
Assistance Publique Hopitaux De Paris
Medical oncology, 27 Rue Du Faubourg Saint Jacques, 75014, Paris
Institut Paoli Calmettes
Medical oncology, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
CHU Besancon
Medical oncology, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex
Centre Hospitalier Et Universitaire De Limoges
Medical oncology, 2 Avenue Martin Luther King, 87000, Limoges
Centre Oscar Lambret
Medical oncology, 3 Rue Frederic Combemale, 59000, Lille
Centre Jean Perrin
Medical oncology, 58 Rue Montalembert, 63011, Clermont Ferrand Cedex1
Centr Georges Francois Leclerc
Medical oncology, 1 Rue Professeur Marion, 21000, Dijon
Institut Gustave Roussy
Medical oncology, 114 Rue Edouard Vaillant, 94800, Villejuif
Oncopole Claudius Regaud
Medical oncology, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Institut Bergonie
Medical oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Institut De Cancerologie De L Ouest
Medical oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Groupe Hospitalier Diaconesses Croix Saint Simon
Medical oncology, 125 Rue D Avron, 75020, Paris
Institut Curie
Medical oncology, 35 Rue Dailly, 92210, Saint-Cloud
Centre Francois Baclesse
Medical oncology, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5
Centre Leon Berard
Medical oncology, 28 Rue Laennec, 69008, Lyon
Centre De Lutte Contre Le Cancer Eugene Marquis
Medical oncology, Avenue La Bataille Flandre Dunkerque, Cs 44229, Rennes Cedex

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-09 France Acceptable
2025-07-08
2025-07-08
2 SUBSTANTIAL MODIFICATION SM-1 2025-09-11 France Acceptable
2025-09-30
2025-09-30
3 SUBSTANTIAL MODIFICATION SM-2 2025-10-16 France Acceptable 2025-10-28